{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:03:54Z","timestamp":1791511434784,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109122"],"award-info":[{"award-number":["JP17ek0109122"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ek0109352"],"award-info":[{"award-number":["JP19ek0109352"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109122"],"award-info":[{"award-number":["JP17ek0109122"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20ek0109352"],"award-info":[{"award-number":["JP20ek0109352"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109122"],"award-info":[{"award-number":["JP17ek0109122"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ek0109352"],"award-info":[{"award-number":["JP19ek0109352"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17ek0109122"],"award-info":[{"award-number":["JP17ek0109122"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ek0109352"],"award-info":[{"award-number":["JP19ek0109352"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Determination of plasma aldosterone concentrations (PAC) and plasma active renin concentrations (ARC) is essential for the diagnosis of primary aldosteronism (PA). In Japan, although PAC and ARC are measured by radioimmunoassay and immunoradiometric assay, respectively, non-radioisotopic methods with better detection sensitivity, measurement accuracy, and technical simplicity are needed. We developed two-site sandwich chemiluminescent enzyme immunoassays (CLEIAs) to measure both PAC and ARC using monoclonal antibodies immobilized onto ferrite particles. The results of both assays are obtained simultaneously from a single plasma sample within 30\u2009min using a fully automated system. The novel CLEIAs were validated using plasma samples from patients with PA (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200952) and essential hypertension (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200923). The PAC determined by the CLEIA was significantly correlated with that measured by liquid chromatography\/mass spectrometry or conventional radioimmunoassay. The ARC determined by the CLEIA was significantly correlated with that measured by immunoradiometric assay. The limits of detection of the CLEIAs for PAC and ARC were 0.1\u2009ng\/dl and 0.04\u2009pg\/ml, respectively, which were better than those of conventional methods (PAC: 2.5\u2009ng\/dl; ARC: 5\u2009pg\/ml). The PAC and PAC\/ARC ratio (ARR) were significantly higher, and the ARC significantly lower, in patients with PA than in those with essential hypertension. An ARR cut-off of 1.31\u2009ng\/dl per pg\/ml showed a sensitivity of 96.2% and specificity of 78.3% for PA screening. The newly developed CLEIAs for measuring PAC and ARC could provide a clinically powerful alternative to conventional methods used for hypertension screening in clinical practice.\n                  <\/jats:p>","DOI":"10.1038\/s41371-020-00465-5","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T14:51:57Z","timestamp":1612882317000},"page":"77-85","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Novel chemiluminescent immunoassay to measure plasma aldosterone and plasma active renin concentrations for the diagnosis of primary aldosteronism"],"prefix":"10.1038","volume":"36","author":[{"given":"Kyoko","family":"Teruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8977-4090","authenticated-orcid":false,"given":"Mitsuhide","family":"Naruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Tsuiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"465_CR1","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1007\/s00268-019-05059-y","volume":"43","author":"OA Shariq","year":"2019","unstructured":"Shariq OA, Mehta K, Thompson GB, Lyden ML, Farley DR, Bancos I, et al. Primary aldosteronism: does underlying pathology impact clinical presentation and outcomes following unilateral adrenalectomy? World J Surg. 2019;43:2469\u201376.","journal-title":"World J Surg"},{"key":"465_CR2","doi-asserted-by":"publisher","unstructured":"Yang Y, Reincke M, Williams TA. Prevalence, Diagnosis and Outcomes of Treatment for Primary Aldosteronism Best Pract Res Clin Endocrinol Metab. 2019:101365. https:\/\/doi.org\/10.1016\/j.beem.2019.101365","DOI":"10.1016\/j.beem.2019.101365"},{"key":"465_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.118.033597","volume":"138","author":"JB Byrd","year":"2018","unstructured":"Byrd JB, Turcu AF, Auchus RJ. Primary aldosteronism. Circulation. 2018;138:823\u201335.","journal-title":"Circulation."},{"key":"465_CR4","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1210\/er.2018-00139","volume":"39","author":"A Vaidya","year":"2018","unstructured":"Vaidya A, Mulatero P, Baudrand R, Adler GK. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev. 2018;39:1057\u201388.","journal-title":"Endocr Rev"},{"key":"465_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"465_CR6","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","volume":"71","author":"Y Ohno","year":"2018","unstructured":"Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, et al. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. Hypertension. 2018;71:530\u20137.","journal-title":"Hypertension."},{"key":"465_CR7","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/HYPERTENSIONAHA.119.12395","volume":"74","author":"GP Rossi","year":"2019","unstructured":"Rossi GP, Maiolino G. Excess arterial damage in hyperaldosteronism. Hypertension. 2019;74:502\u20134.","journal-title":"Hypertension."},{"key":"465_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1507\/endocrj.EJ11-0133","volume":"58","author":"T Nishikawa","year":"2011","unstructured":"Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, et al. Guidelines for the diagnosis and treatment of primary aldosteronism \u2013 The Japan Endocrine Society 2009. Endocr J. 2011;58:711\u20137.","journal-title":"Endocr J."},{"key":"465_CR9","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889\u2013916.","journal-title":"J Clin Endocrinol Metab"},{"key":"465_CR10","first-page":"6","volume":"35","author":"T Ujike","year":"2018","unstructured":"Ujike T, Uemura M, Mukai K, Kozawa J, Otsuki M, Takao T, et al. The latest consensus statement on the clinical practice of primary aldosteronism in Japan. Off J Jpn Assoc Endocr Surg Jpn Soc Thyroid Surg. 2018;35:6\u20137.","journal-title":"Off J Jpn Assoc Endocr Surg Jpn Soc Thyroid Surg"},{"key":"465_CR11","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1210\/jc.2018-01041","volume":"103","author":"Z Guo","year":"2018","unstructured":"Guo Z, Poglitsch M, McWhinney BC, Ungerer JPJ, Ahmed AH, Gordon RD, et al. Aldosterone LC-MS\/MS assay-specific threshold values in screening and confirmatory testing for primary aldosteronism. J Clin Endocrinol Metab. 2018;103:3965\u201373.","journal-title":"J Clin Endocrinol Metab"},{"key":"465_CR12","unstructured":"Japan Health Policy Now, http:\/\/japanhpn.org\/en\/home-1\/"},{"key":"465_CR13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1507\/endocrj.EJ16-0304","volume":"63","author":"T Nishikawa","year":"2016","unstructured":"Nishikawa T, Omura M, Kawaguchi M, Takatsu A, Satoh F, Ito S, et al. Calibration and evaluation of routine methods by serum certified reference material for aldosterone measurement in blood. Endocr J. 2016;63:1065\u201380.","journal-title":"Endocr J."},{"key":"465_CR14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1161\/HYPERTENSIONAHA.117.09078","volume":"70","author":"R Morimoto","year":"2017","unstructured":"Morimoto R, Ono Y, Tezuka Y, Kudo M, Yamamoto S, Arai T, et al. Rapid screening of primary aldosteronism by a novel chemiluminescent immunoassay. Hypertension. 2017;70:334\u201341.","journal-title":"Hypertension."},{"key":"465_CR15","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/clinchem\/37.9.1639","volume":"37","author":"I Nishizono","year":"1991","unstructured":"Nishizono I, Iida S, Suzuki N, Kawada H, Murakami H, Ashihara Y, et al. Rapid and sensitive chemiluminescent enzyme immunoassay for measuring reference tumor markers. Clin Chem. 1991;37:1639\u201344.","journal-title":"Clin Chem"},{"key":"465_CR16","unstructured":"National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan, https:\/\/www.nmij.jp\/service\/C\/"},{"key":"465_CR17","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1210\/jc.2003-031337","volume":"89","author":"P Mulatero","year":"2004","unstructured":"Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centres from five continents. J Clin Endocrinol Metab. 2004;89:1045\u201350.","journal-title":"J Clin Endocrinol Metab"},{"key":"465_CR18","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811\u201320.","journal-title":"J Am Coll Cardiol"},{"key":"465_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","volume":"168","author":"C Catena","year":"2008","unstructured":"Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80\u201385.","journal-title":"Arch Intern Med"},{"key":"465_CR20","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"465_CR21","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1210\/jc.2013-2805","volume":"98","author":"P Mulatero","year":"2013","unstructured":"Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98:4826\u201333.","journal-title":"J Clin Endocrinol Metab"},{"key":"465_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","volume":"62","author":"S Savard","year":"2013","unstructured":"Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62:331\u2013336.","journal-title":"Hypertension."},{"key":"465_CR23","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1373\/clinchem.2004.033159","volume":"50","author":"FH Perschel","year":"2004","unstructured":"Perschel FH, Schemer R, Seiler L, Reincke M, Deinum J, Maser-Gluth C, et al. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem. 2004;50:1650\u20135.","journal-title":"Clin Chem"},{"key":"465_CR24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/HJH.0000000000000880","volume":"34","author":"J Burrello","year":"2016","unstructured":"Burrello J, Monticone S, Buffolo F, Lucchiari M, Tetti M, Rabbia F, et al. Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. J Hypertens. 2016;34:920\u20137.","journal-title":"J Hypertens"},{"key":"465_CR25","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1515\/cclm-2015-1094","volume":"54","author":"GP Rossi","year":"2016","unstructured":"Rossi GP, Ceolotto G, Rossitto G, Seccia TM, Maiolino G, Berton C, et al. Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension. Clin Chem Lab Med. 2016;54:1441\u201350.","journal-title":"Clin Chem Lab Med"},{"key":"465_CR26","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1097\/HJH.0000000000000727","volume":"33","author":"J Manolopoulou","year":"2015","unstructured":"Manolopoulou J, Fischer E, Dietz A, Diederich S, Holmes D, Junnila R, et al. Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. J Hypertens. 2015;33:2500\u201311.","journal-title":"J Hypertens"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-00465-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-00465-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-00465-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T04:24:44Z","timestamp":1642479884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-00465-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1038\/s41371-020-00465-5","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"assertion":[{"value":"15 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was conducted in part by the research expenses provided by the research contract between NHO Kyoto Medical Center and Fujirebio Inc. (Tokyo, Japan). MN received lecture fees from Daiichi Sankyo Co., Ltd. and Kyowa Kirin Co., Ltd.. The authors declare that no conflicts of interest related to employment, leadership positions, or honoraria.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}